{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"iTHYM","nct_id":"NCT06750952","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ithym-nct06750952. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"iTHYM","arms":[{"description":"Ivonescimab combined with chemotherapy：Ivonescimab，20mg/kg， iv. drip, D1, Q3W；Paclitaxel, 175mg/m2 or albumin paclitaxel, 260mg/m2, iv. drip, D1, Q3W；Carboplatin, AUC5， iv.drip,D1, Q3W。After 4-6 cycles of combination therapy, Ivonescimab was maintained until PD or toxicity was intolerable.","label":"Ivonescimab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-20","type":"ESTIMATED"},"conditions":["Relapsed or Metastatic Thymic Cancer","First-line Treatment"],"enrollment":{"count":24,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ivonescimab Combined With Chemotherapy","otherNames":["AK112"],"type":"DRUG"}],"last_update":"2024-12-27","lead_sponsor":"Sun Yat-sen University","official_title":"Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial (iTHYM)","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival at 6 months（PFS 6m）","timeFrame":"Within one year after starting treatment."}],"references":[],"start_date":{"date":"2024-12-20","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial","url":"https://clinicaltrials.gov/study/NCT06750952"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ithym-nct06750952"}